Our core philosophy is that cancer therapies need not be toxic to the patient

 

The OncoLife Therapeutics developmental platform is designed around the understanding that both investors and cancer patients suffer from the same risk, which is that a therapy will be too toxic to be effective.

For the investor, money is lost on a failed venture. For the patient, the opportunity for a cure is lost.  

Our core philosophy is that cancer therapies need not be toxic to the patient. All targets that are active in healthy tissues are eliminated prior to any laboratory testing, eliminating the risk of toxic side effects that derail so many therapies.

As a result, we offer greatly minimised risk profiles: Both for investors and patients.